PubRank

M Juliana McElrath

Author PubWeight™ 198.89‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008 19.65
2 Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012 12.98
3 The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010 9.61
4 Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 2007 6.36
5 Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods 2007 4.69
6 A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis 2007 3.95
7 Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. J Immunol Methods 2007 3.29
8 A Blueprint for HIV Vaccine Discovery. Cell Host Microbe 2012 3.27
9 Setting the stage: host invasion by HIV. Nat Rev Immunol 2008 3.25
10 Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 2013 3.24
11 Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity. J Infect Dis 2003 2.98
12 Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med 2011 2.71
13 Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection. J Virol 2003 2.64
14 Selection on the human immunodeficiency virus type 1 proteome following primary infection. J Virol 2006 2.48
15 Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog 2009 2.36
16 Evolution of CD8+ T cell immunity and viral escape following acute HIV-1 infection. J Immunol 2003 2.21
17 Preservation of T cell proliferation restricted by protective HLA alleles is critical for immune control of HIV-1 infection. J Immunol 2006 2.17
18 Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion. J Infect Dis 2003 2.04
19 A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. J Infect Dis 2011 1.99
20 Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine 2006 1.97
21 A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One 2011 1.81
22 Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr 2007 1.73
23 Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest 2011 1.73
24 Protective HIV-specific CD8+ T cells evade Treg cell suppression. Nat Med 2011 1.66
25 Repeat-region polymorphisms in the gene for the dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin-related molecule: effects on HIV-1 susceptibility. J Infect Dis 2006 1.62
26 Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection. J Virol 2006 1.62
27 Development of an automated analysis system for data from flow cytometric intracellular cytokine staining assays from clinical vaccine trials. Cytometry A 2008 1.54
28 Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054). PLoS One 2010 1.53
29 Human immunodeficiency virus type 1 mediates global disruption of innate antiviral signaling and immune defenses within infected cells. J Virol 2009 1.53
30 High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. J Infect Dis 2005 1.49
31 Merck Ad5/HIV induces broad innate immune activation that predicts CD8⁺ T-cell responses but is attenuated by preexisting Ad5 immunity. Proc Natl Acad Sci U S A 2012 1.46
32 Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies. J Virol 2007 1.44
33 Analysis of genetic polymorphisms in CCR5, CCR2, stromal cell-derived factor-1, RANTES, and dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in seronegative individuals repeatedly exposed to HIV-1. J Infect Dis 2004 1.41
34 Demographic processes affect HIV-1 evolution in primary infection before the onset of selective processes. J Virol 2011 1.41
35 Virus-specific CD8+ T-cell responses better define HIV disease progression than HLA genotype. J Virol 2010 1.39
36 Statistical considerations for the design and analysis of the ELISpot assay in HIV-1 vaccine trials. J Immunol Methods 2004 1.37
37 Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms. J Biol Chem 2010 1.36
38 Genomewide association study for determinants of HIV-1 acquisition and viral set point in HIV-1 serodiscordant couples with quantified virus exposure. PLoS One 2011 1.35
39 Evolution of human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitopes: fitness-balanced escape. J Virol 2007 1.35
40 Enhanced detection of human immunodeficiency virus type 1 (HIV-1) Nef-specific T cells recognizing multiple variants in early HIV-1 infection. J Virol 2007 1.32
41 Equivalence of ELISpot assays demonstrated between major HIV network laboratories. PLoS One 2010 1.30
42 Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission. J Virol 2005 1.30
43 Persistence of extraordinarily low levels of genetically homogeneous human immunodeficiency virus type 1 in exposed seronegative individuals. J Virol 2003 1.28
44 Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines. J Infect Dis 2004 1.28
45 Post-step modifications for research on HIV vaccines. AIDS 2009 1.26
46 HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable. J Immunol 2011 1.21
47 Dynamics of viral evolution and CTL responses in HIV-1 infection. PLoS One 2011 1.21
48 Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). J Infect Dis 2012 1.21
49 Polymorphisms in toll-like receptor 4 and toll-like receptor 9 influence viral load in a seroincident cohort of HIV-1-infected individuals. AIDS 2009 1.20
50 Host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the step trial. J Infect Dis 2011 1.20
51 Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acquir Immune Defic Syndr 2002 1.20
52 Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160. J Infect Dis 2004 1.20
53 Vaginal langerhans cells nonproductively transporting HIV-1 mediate infection of T cells. J Virol 2011 1.19
54 FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. J Clin Invest 2014 1.18
55 Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization. J Virol 2010 1.18
56 Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study. PLoS One 2011 1.16
57 OMIP-014: validated multifunctional characterization of antigen-specific human T cells by intracellular cytokine staining. Cytometry A 2012 1.15
58 Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial. PLoS One 2011 1.13
59 A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. Vaccine 2011 1.11
60 Progress in HIV-1 vaccine development. Curr Opin HIV AIDS 2013 1.09
61 Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity. PLoS One 2010 1.09
62 Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies. PLoS One 2010 1.08
63 Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. Vaccine 2008 1.06
64 HIV vaccines: mosaic approach to virus diversity. Nat Med 2010 1.05
65 Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors. J Virol 2012 1.05
66 Vpu mediates depletion of interferon regulatory factor 3 during HIV infection by a lysosome-dependent mechanism. J Virol 2012 1.05
67 Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection. J Infect Dis 2013 1.04
68 Early induction and maintenance of Env-specific T-helper cells following human immunodeficiency virus type 1 infection. J Virol 2003 1.04
69 Priming CD8+ T cells with dendritic cells matured using TLR4 and TLR7/8 ligands together enhances generation of CD8+ T cells retaining CD28. Blood 2011 1.04
70 Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans. PLoS One 2011 1.04
71 HIV-1 vaccination administered intramuscularly can induce both systemic and mucosal T cell immunity in HIV-1-uninfected individuals. J Immunol 2003 1.03
72 MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load. PLoS One 2012 1.03
73 Most highly exposed seronegative men lack HIV-1-specific, IFN-gamma-secreting T cells. J Immunol 2003 1.01
74 Trivalent adenovirus type 5 HIV recombinant vaccine primes for modest cytotoxic capacity that is greatest in humans with protective HLA class I alleles. PLoS Pathog 2011 1.00
75 Comprehensive epitope analysis of cross-clade Gag-specific T-cell responses in individuals with early HIV-1 infection in the US epidemic. Vaccine 2006 1.00
76 Association of T cell proliferative responses and phenotype with virus control in chronic progressive HIV-1 disease. J Infect Dis 2004 0.97
77 Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein. J Infect Dis 2004 0.97
78 Correlation between interferon- gamma secretion and cytotoxicity, in virus-specific memory T cells. J Infect Dis 2004 0.96
79 Conserved HIV-1 epitopes continuously elicit subdominant cytotoxic T-lymphocyte responses. J Infect Dis 2009 0.96
80 Quantifying ongoing HIV-1 exposure in HIV-1-serodiscordant couples to identify individuals with potential host resistance to HIV-1. J Infect Dis 2012 0.94
81 Absence of immunodominant anti-Gag p17 (SL9) responses among Gag CTL-positive, HIV-uninfected vaccine recipients expressing the HLA-A*0201 allele. J Immunol 2004 0.94
82 Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study. AIDS 2011 0.94
83 Vpu-deficient HIV strains stimulate innate immune signaling responses in target cells. J Virol 2012 0.93
84 Optimization and qualification of a multiplex bead array to assess cytokine and chemokine production by vaccine-specific cells. J Immunol Methods 2012 0.93
85 Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects. J Infect Dis 2011 0.92
86 Host genetic polymorphisms associated with innate immune factors and HIV-1. Curr Opin HIV AIDS 2011 0.92
87 Human CD1a deficiency is common and genetically regulated. J Immunol 2013 0.92
88 Broadly increased sensitivity to cytotoxic T lymphocytes resulting from Nef epitope escape mutations. J Immunol 2003 0.91
89 Preinfection human immunodeficiency virus (HIV)-specific cytotoxic T lymphocytes failed to prevent HIV type 1 infection from strains genetically unrelated to viruses in long-term exposed partners. J Virol 2009 0.91
90 Toll-like receptor polymorphism associations with HIV-1 outcomes among sub-Saharan Africans. J Infect Dis 2013 0.91
91 In situ detection of Gag-specific CD8+ cells in the GI tract of SIV infected Rhesus macaques. Retrovirology 2010 0.90
92 Novel cytotoxic T-lymphocyte escape mutation by a three-amino-acid insertion in the human immunodeficiency virus type 1 p6Pol and p6Gag late domain associated with drug resistance. J Virol 2007 0.90
93 HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1. PLoS Pathog 2013 0.90
94 Optimization and qualification of a memory B-cell ELISpot for the detection of vaccine-induced memory responses in HIV vaccine trials. J Immunol Methods 2013 0.90
95 Vaccine-induced HIV-specific CD8+ T cells utilize preferential HLA alleles and target-specific regions of HIV-1. J Acquir Immune Defic Syndr 2011 0.88
96 HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial. J Clin Invest 2014 0.88
97 Profiling immunity to HIV vaccines with systems biology. Curr Opin HIV AIDS 2012 0.88
98 Induction of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses in HIV vaccine trial participants who subsequently acquire HIV-1 infection. J Virol 2006 0.86
99 Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination. PLoS One 2012 0.86
100 T cell responses generated by HIV vaccines in clinical trials. Curr Opin HIV AIDS 2008 0.86
101 Enumeration of major peripheral blood leukocyte populations for multicenter clinical trials using a whole blood phenotyping assay. J Vis Exp 2012 0.85
102 Increased sequence coverage through combined targeting of variant and conserved epitopes correlates with control of HIV replication. J Virol 2013 0.85
103 Differential regulatory T cell activity in HIV type 1-exposed seronegative individuals. AIDS Res Hum Retroviruses 2013 0.84
104 Association between peripheral γδ T-cell profile and disease progression in individuals infected with HIV-1 or HIV-2 in West Africa. J Acquir Immune Defic Syndr 2011 0.83
105 Most DC-SIGNR transcripts at mucosal HIV transmission sites are alternatively spliced isoforms. Eur J Hum Genet 2005 0.81
106 A novel HIV vaccine adjuvanted by IC31 induces robust and persistent humoral and cellular immunity. PLoS One 2012 0.80
107 CD4+ T cell receptor repertoire perturbations in HIV-1 infection: association with plasma viremia and disease progression. Clin Immunol 2006 0.80
108 Abacavir hypersensitivity reaction in primary HIV infection. AIDS 2006 0.80
109 Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial. Ann Intern Med 2016 0.80
110 Role of human immunodeficiency virus (HIV)-specific T-cell immunity in control of dual HIV-1 and HIV-2 infection. J Virol 2007 0.80
111 Effect of adjunct hydroxyurea on helper T cell immunity in HIV type 1-infected patients with virological suppression. AIDS Res Hum Retroviruses 2004 0.80
112 Two new monoclonal antibodies for biochemical and flow cytometric analyses of human interferon regulatory factor-3 activation, turnover, and depletion. Methods 2012 0.77
113 OMIP-025: evaluation of human T- and NK-cell responses including memory and follicular helper phenotype by intracellular cytokine staining. Cytometry A 2014 0.77
114 Impaired viral entry cannot explain reduced CD4+ T cell susceptibility to HIV type 1 in certain highly exposed individuals. AIDS Res Hum Retroviruses 2008 0.76
115 Hepatitis C virus-specific cytolytic T cell responses after antiviral therapy. Clin Immunol 2003 0.76
116 HIV Vaccine Trials Network: activities and achievements of the first decade and beyond. Clin Investig (Lond) 2012 0.76
117 OMIP-024: pan-leukocyte immunophenotypic characterization of PBMC subsets in human samples. Cytometry A 2014 0.75
118 Herpes Simplex Virus Suppressive Therapy in Herpes Simplex Virus-2/Human Immunodeficiency Virus-1 Coinfected Women Is Associated With Reduced Systemic CXCL10 But Not Genital Cytokines. Sex Transm Dis 2016 0.75
119 Regulatory T-Cell Activity But Not Conventional HIV-Specific T-Cell Responses Are Associated With Protection From HIV-1 Infection. J Acquir Immune Defic Syndr 2016 0.75
120 Progress in the development of a preventive HIV-1 vaccine. Clin Lab Med 2002 0.75
121 Correction: Musosal effects for tenofovir 1% gel. Elife 2015 0.75
122 Correction: Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. PLoS Pathog 2017 0.75